MiniMed Group Inc

MMEDHealthcare·Medical Instruments & Supplies·USA·Mid·NASD·Nov 11 • 1:17 PM ET

18.25+0.89 (5.12%)

2026-11-11 19:18 CET

Market cap

4,884.24 USD m

Revenue, TTM

843.00 USD m

Net income, TTM

0.00 USD m

Free cash flow, TTM

-90.00 USD m

EPS diluted, TTM

0.00

P/E

Compare

Price

MMED against its 20 and 50-day averages

2050miss

25.3% under the 52-week high of 24.43 on 2 Sep 2026. 52-week low 10.65 on 15 May 2026. Last 15 sessions, 19.6% high to low

Profile

MMED

52-week range, 55% of the way up

10.6524.43

MiniMed Group, Inc. engages in the development, manufacturing, and marketing of a wide range of medical devices and solutions for diabetes management. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets, software platforms, and related accessories that help patients and healthcare providers effectively monitor and control blood glucose levels. The company was founded by Alfred E. Mann in 1983 and is headquartered in Northridge, CA.

Index	RUT
Employees	8000
IPO	Mar 06, 2026
ATR, 14d	1.01
Rel volume	0.60
Short float	3.51%
Insider own	0.55%
Inst own	21.18%

Snapshot

6 groups

Valuation

Index	RUT
Market Cap	5.13B
Enterprise Value	4.99B
Income	-
Sales	-
Book/sh	12.87
Cash/sh	0.74
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8000
IPO	Mar 06, 2026

Ratios

P/E	-
Forward P/E	25.58
PEG	-
P/S	-
P/B	1.42
P/C	24.80
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.36
Current Ratio	1.81
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

Earnings

EPS (ttm)	-
EPS next Y	0.71
EPS next Q	-
EPS this Y	154.22%
EPS next Y	2.00%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	100.00%
Sales Q/Q	16.44%
Earnings	Nov 24 BMO
EPS/Sales Surpr.	-356.07% 1.01%

Ownership

Insider Own	0.55%
Insider Trans	0.00%
Inst Own	21.18%
Inst Trans	2.04%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.02%
SMA50	-8.02%
SMA200	9.47%
Trades	-

Technical

Shs Outstand	281.21M
Shs Float	279.80M
Short Float	3.51%
Short Ratio	1.26
Short Interest	9.81M
52W High	24.43 -25.30%
52W Low	10.65 71.36%
Volatility	6.75% 5.44%
ATR (14)	1.01
RSI (14)	47.80
Beta	-
Rel Volume	0.60
Avg Volume	7.81M
Volume	2,818,083

Performance

Perf Week	-5.39%
Perf Month	-0.82%
Perf Quarter	-8.84%
Perf Half Y	63.23%
Perf YTD	-4.20%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.61
Target Price	25.87
Prev Close	17.36
Price	18.25
Change %	5.12%

Analyst ratings

latest 10 of 17

Date	Action	Analyst	Rating change	Target	Implied
Oct 13, 2026	Initiated	RRothschild & Co Redburn	Buy	$30	+64.4%
Oct 12, 2026	Initiated	JJefferies	Hold	$22	+20.6%
Oct 07, 2026	Initiated	BBarclays	Equal Weight	$22	+20.6%
Sep 24, 2026	Initiated	TTruist	Buy	$29	+58.9%
Jul 28, 2026	Initiated	UUBS	Buy	$25	+37.0%
May 12, 2026	Initiated	TThe Benchmark Company	Buy	$20	+9.6%
Mar 31, 2026	Initiated	WWilliam Blair	Outperform
Mar 31, 2026	Initiated	WWells Fargo	Overweight	$26	+42.5%
Mar 31, 2026	Initiated	PPiper Sandler	Neutral	$16	-12.3%
Mar 31, 2026	Initiated	MMorgan Stanley	Overweight	$19	+4.1%

Date

Action

Analyst

Rating change

Target

Implied

Oct 13, 2026

Initiated

RRothschild & Co Redburn

Buy

$30

+64.4%

Oct 12, 2026

Initiated

JJefferies

Hold

$22

+20.6%

Oct 07, 2026

Initiated

BBarclays

Equal Weight

$22

+20.6%

Sep 24, 2026

Initiated

TTruist

Buy

$29

+58.9%

Jul 28, 2026

Initiated

UUBS

Buy

$25

+37.0%

May 12, 2026

Initiated

TThe Benchmark Company

Buy

$20

+9.6%

Mar 31, 2026

Initiated

WWilliam Blair

Outperform

Mar 31, 2026

Initiated

WWells Fargo

Overweight

$26

+42.5%

Mar 31, 2026

Initiated

PPiper Sandler

Neutral

$16

-12.3%

Mar 31, 2026

Initiated

MMorgan Stanley

Overweight

$19

+4.1%

Peers

Mkt cap

Ticker	Company	Mkt cap
PODD	Insulet Corp	10.32B
TNDM	Tandem Diabetes Care Inc	1.32B
BBNX	Beta Bionics Inc	953.05M
DXCM	Dexcom Inc	29.91B
EMBC	Embecta Corp	368.27M
ABT	Abbott Laboratories	190.26B
SENS	Senseonics Holdings Inc	580.73M
BDX	Becton Dickinson & Co	57.74B
NVO	Novo Nordisk ADR	136.14B
LLY	Lilly(Eli) & Co	1342.23B

Ticker

Company

Mkt cap

PODD

Insulet Corp

10.32B

TNDM

Tandem Diabetes Care Inc

1.32B

BBNX

Beta Bionics Inc

953.05M

DXCM

Dexcom Inc

29.91B

EMBC

Embecta Corp

368.27M

ABT

Abbott Laboratories

190.26B

SENS

Senseonics Holdings Inc

580.73M

BDX

Becton Dickinson & Co

57.74B

NVO

Novo Nordisk ADR

136.14B

LLY

Lilly(Eli) & Co

1342.23B

Held by

AUM

Ticker	Company	AUM
IWM	iShares Russell 2000 Index Fund	AUM: 77.38B
IWN	iShares Russell 2000 Value ETF	AUM: 14.10B
SCHA	Schwab U.S. Small-Cap ETF	AUM: 22.25B
FESM	Fidelity Enhanced Small Cap Core ETF	AUM: 6.82B
FPX	First Trust US Equity Opportunities ETF	AUM: 1.34B
ITOT	iShares Core S&P Total U.S. Stock Market ETF	AUM: 95.28B
VXF	Vanguard Extended Market Index ETF	AUM: 30.47B
VTWO	Vanguard Russell 2000 Index ETF	AUM: 16.75B
SCHB	Schwab U.S. Broad Market ETF	AUM: 44.09B
MGMT	Ballast Small/Mid Cap ETF	AUM: 166.52M

Ticker

Company

AUM

IWM

iShares Russell 2000 Index Fund

AUM: 77.38B

IWN

iShares Russell 2000 Value ETF

AUM: 14.10B

SCHA

Schwab U.S. Small-Cap ETF

AUM: 22.25B

FESM

Fidelity Enhanced Small Cap Core ETF

AUM: 6.82B

FPX

First Trust US Equity Opportunities ETF

AUM: 1.34B

ITOT

iShares Core S&P Total U.S. Stock Market ETF

AUM: 95.28B

VXF

Vanguard Extended Market Index ETF

AUM: 30.47B

VTWO

Vanguard Russell 2000 Index ETF

AUM: 16.75B

SCHB

Schwab U.S. Broad Market ETF

AUM: 44.09B

MGMT

Ballast Small/Mid Cap ETF

AUM: 166.52M

News

latest 14 of 104

Nov-05-26 08:00AMMiniMed to Participate in Upcoming Investor Conferences (PR Newswire) -5.88%
Nov-04-26 04:15PMMiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results (PR Newswire)
Nov-03-26 09:20AMMiniMed Appoints Dr. David Segal as Chief Medical Officer (PR Newswire)
Oct-16-26 08:41AMMiniMed Announces Board of Directors for its Next Chapter as an Independent Company (PR Newswire)
Oct-15-26 05:01PMIs Medtronic Stock A Buy Now That Sales Growth Has Picked Up? (Trefis) +7.08%
04:10PMMiniMed Announces Board of Directors for its Next Chapter as an Independent Company (PR Newswire)
10:00AMMiniMed Completes Separation from Medtronic (PR Newswire)
10:00AMMedtronic Completes Separation of MiniMed Group, Inc. (PR Newswire)
Oct-14-26 08:00AMMedtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer (PR Newswire) -8.64%
Oct-13-26 09:43AMAdobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls (The Fly)
Oct-12-26 08:45AMMedtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer (PR Newswire)
Oct-07-26 05:31PMMedtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc. (PR Newswire)
10:00AMFlutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
Oct-06-26 08:18AMIf The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock? (Trefis)

Key figures

Revenue, TTM	843.00
Net income, TTM	0.00
EPS diluted, TTM	0.00
EBIT, TTM	65.00
Free cash flow, TTM	-90.00
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	4,884.24
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
2026Q1	2026-09-01	0.120	0.124	0.000	843	826.8	4
2025Q4	2026-06-03	-0.680	-0.149	-0.680	837	828.61	11
2026Q2	-	-	0.132	-	-	825.06	12
2026Q3	-	-	0.212	-	-	860.77	12
2026Q4	-	-	0.307	-	-	905.78	12
2027Q1	-	-	0.042	-	-	887.76	8
2027Q2	-	-	-0.132	-	-	908.26	7
2027Q3	-	-	0.288	-	-	940.96	7
2027Q4	-	-	0.384	-	-	994.85	7
2028Q1	-	-	0.398	-	-	946.56	2
2028Q2	-	-	0.434	-	-	994.51	2
2028Q3	-	-	0.458	-	-	1,040	2
2028Q4	-	-	0.524	-	-	1,096	2

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
2025FY	-1.290	0.330	-1.290	3,102	3,088
2026FY	-	0.699	-	-	3,439
2027FY	-	0.713	-	-	3,720
2028FY	-	1.702	-	-	4,089
2029FY	-	2.312	-	-	4,533
2030FY	-	3.200	-	-	5,050

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
2026Q2	S	2026-10-13	12	2	3	825.06	813.92	832.83
2026Q2	S	2026-10-12	12	2	3	825.15	813.92	832.83
2026Q2	S	2026-10-09	12	1	4	824.32	813.92	832
2026Q2	S	2026-10-02	11	1	3	825.14	813.92	832.8
2026Q2	S	2026-09-27	10	1	3	825.76	813.92	832.8
2026Q2	S	2026-09-23	10	1	4	825.76	813.92	832.8
2026Q2	S	2026-09-17	9	1	4	825.27	813.92	832.8
2026Q2	S	2026-09-14	9	1	3	826.37	813.92	836.88
2026Q2	S	2026-09-01	10	2	3	826.42	813.92	836.88
2026Q2	S	2026-08-24	10	1	1	830.75	816.86	841
2026Q2	S	2026-08-18	10	0	1	829.9	816.86	841
2026Q2	S	2026-08-17	10	0	2	829.9	816.86	841
2026Q2	S	2026-08-13	10	3	2	829.9	816.86	841
2026Q2	S	2026-08-10	10	3	2	829.93	816.86	841.3

Estimate history

Period	2024	2025
EPS, annual	-0.759	-1.186
EPS, quarterly	-0.036	-0.613	-0.068	-0.424	-0.652	0
Period	Q3 '24	Q4 '24	Q1 '25	Q3 '25	Q4 '25	Q1 '26
Sales, annual	2715	3102
Period	2024	2025
Sales, quarterly	687	724	723	790	837	843
Period	Q3 '24	Q4 '24	Q1 '25	Q3 '25	Q4 '25	Q1 '26
Shares, annual	280.82	280.82	281.206
Period	2024	2025	MRQ
Shares, quarterly	280.82	280.82	280.82	280.82	280.82	281.206
Period	Q3 '24	Q4 '24	Q1 '25	Q3 '25	Q4 '25	Q1 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Total Revenue	843.00	3,102.00	2,715.00
Cost of Goods Sold Incl. D&A	379.00	1,298.00	1,152.00
Gross Profit	464.00	1,804.00	1,563.00
Selling, General and Administrative Excl. Other	399.00	1,373.00	1,220.00
Research and Development	115.00	421.00	408.00
Other Operating Expense	0.00	0.00	0.00
Operating Income	65.00	431.00	343.00
Interest Expense	0.00	0.00	0.00
Unusual Expense	27.00	453.00	522.00
Net Income Before Taxes	4.00	-189.00	-147.00
Income Taxes	4.00	128.00	52.00
Consolidated Net Income	0.00	-317.00	-198.00
Net Income From Continuing Operations	0.00	-333.00	-213.00
Net Income	0.00	-333.00	-213.00
EPS (Recurring)	0.07	-0.06	0.54
EPS (Basic, Before Extraordinaries)	0.00	-1.19	-0.76
EPS (Diluted)	0.00	-1.19	-0.76
EBITDA	106.00	587.00	486.00
Non-Operating Income (Expense)	-34.00	-167.00	32.00
Other After Tax Adjustments	0.00	0.00	1.00
Stock Option Compensation Expense	7.90	39.00	27.65
Price To Sales Ratio	-	1.19	-
Gross Margin	-	58.16	57.57
Operating Margin	-	13.89	12.63
Net Margin	-	-10.74	-7.85
Shares Outstanding	281.21	280.82	280.82
Market Capitalization	4,884.24	4,884.24	3,375.46

Income statement, quarterly

Currency USD, millions
Metric	2026Q1	2025Q4	2025Q3	2025Q1	2024Q4	2024Q3
Total Revenue	843.00	837.00	790.00	723.00	724.00	687.00
Cost of Goods Sold Incl. D&A	379.00	355.00	327.00	304.00	311.00	282.00
Gross Profit	464.00	482.00	463.00	419.00	413.00	405.00
Selling, General and Administrative Excl. Other	399.00	372.00	344.00	314.00	320.00	302.00
Research and Development	115.00	96.00	104.00	117.00	102.00	104.00
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	65.00	110.00	119.00	105.00	93.00	103.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Unusual Expense	27.00	33.00	222.00	125.00	255.00	90.00
Net Income Before Taxes	4.00	-90.00	-99.00	-13.00	-148.00	21.00
Income Taxes	4.00	93.00	12.00	3.00	21.00	28.00
Consolidated Net Income	0.00	-183.00	-111.00	-16.00	-167.00	-7.00
Net Income From Continuing Operations	0.00	-183.00	-119.00	-19.00	-172.00	-10.00
Net Income	0.00	-183.00	-119.00	-19.00	-172.00	-10.00
EPS (Recurring)	0.07	-0.57	0.13	0.24	0.02	0.19
EPS (Basic, Before Extraordinaries)	0.00	-0.65	-0.42	-0.07	-0.61	-0.04
EPS (Diluted)	0.00	-0.65	-0.42	-0.07	-0.61	-0.04
EBITDA	106.00	149.00	158.00	144.00	131.00	140.00
Non-Operating Income (Expense)	-34.00	-167.00	3.00	6.00	14.00	9.00
Other After Tax Adjustments	0.00	0.00	0.00	0.00	2.00	0.00
Stock Option Compensation Expense	7.90	9.00	9.00	7.11	8.00	10.00
Gross Margin	55.04	57.59	58.61	57.95	57.04	58.95
Operating Margin	7.71	13.14	15.06	14.52	12.85	14.99
Net Margin	0.00	-21.86	-15.06	-2.63	-23.76	-1.46
Shares Outstanding	281.21	280.82	280.82	280.82	280.82	280.82
Market Capitalization	4,884.24	3,465.32	3,375.46	-	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY
Cash & Short Term Investments	298.00	11.00
Short Term Receivables	655.00	570.00
Inventories	341.00	311.00
Other Current Assets	54.00	47.00
Total Current Assets	1,348.00	939.00
Net Property, Plant & Equipment	763.00	772.00
Total Investments and Advances	75.00	75.00
Intangible Assets	2,363.00	2,387.00
Deferred Tax Assets	61.00	19.00
Other Assets	20.00	9.00
Total Assets	4,630.00	4,201.00
Short Term Debt Incl. Current Port. of LT Debt	8.00	11.00
Accounts Payable	163.00	205.00
Income Tax Payable	38.00	0.00
Other Current Liabilities	493.00	494.00
Total Current Liabilities	702.00	710.00
Long Term Debt	45.00	56.00
Provision for Risks Charges	59.00	80.00
Other Liabilities	213.00	25.00
Total Liabilities	1,019.00	871.00
Non-Equity Reserves	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00
Common Equity	3,611.00	3,330.00
Total Shareholders Equity	3,611.00	3,330.00
Accumulated Minority Interest	0.00	0.00
Total Equity	3,611.00	3,330.00
Total Liabilities & Stockholders Equity	4,630.00	4,201.00
Book Value Per Share	12.86	11.86
Tangible Book Value Per Share	4.44	3.36
Full-Time Employees	8,000	-
Price to Book Ratio	1.35	0.97
Return on Assets	-7.54	-
Return on Equity	-9.60	-
Return on Invested Capital	-9.11	-6.29
Quick Ratio	1.43	0.88
Current Ratio	1.92	1.32

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Net Income	0.00	-317.00	-198.00
Depreciation	41.00	156.00	143.00
Other Funds (Non Cash)	18.00	184.00	75.00
Funds from Operations	61.00	-31.00	18.00
Extraordinary Item	0.00	0.00	0.00
Changes in Working Capital	-110.00	-166.00	122.00
Cash from Operating Activities	-49.00	-197.00	140.00
Capital Expenditures	-41.00	-223.00	-193.00
Net Assets From Acquisitions	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00
Other Uses	0.00	-10.00	0.00
Other Sources	0.00	0.00	0.00
Cash from Investing Activities	-41.00	-233.00	-193.00
Cash Dividends Paid	0.00	-229.00	-2.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00
Change in Capital Stock	0.00	538.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	538.00	0.00
Proceedsfrom Stock Options	0.00	538.00	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	407.00	12.00
Other Financing Activities Uses	0.00	0.00	0.00
Cash from Financing Activities	0.00	716.00	10.00
Exchange Rate Effect	-1.00	1.00	0.00
Net Change in Cash	-91.00	287.00	-43.00
Free Cash Flow	-90.00	-420.00	-53.00
Deferred Taxes & Investment Tax Credit	-	-54.00	-2.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q1	2025Q4	2025Q3	2025Q1	2024Q4	2024Q3
Cash & Short Term Investments	207.00	298.00	10.00	-	11.00	-
Short Term Receivables	782.00	655.00	653.00	-	570.00	-
Inventories	356.00	341.00	408.00	-	311.00	-
Other Current Assets	72.00	54.00	37.00	-	47.00	-
Total Current Assets	1,417.00	1,348.00	1,108.00	-	939.00	-
Net Property, Plant & Equipment	793.00	763.00	761.00	-	772.00	-
Total Investments and Advances	75.00	75.00	75.00	-	75.00	-
Intangible Assets	2,355.00	2,363.00	2,369.00	-	2,387.00	-
Deferred Tax Assets	58.00	61.00	19.00	-	19.00	-
Other Assets	20.00	20.00	11.00	-	9.00	-
Total Assets	4,718.00	4,630.00	4,343.00	-	4,201.00	-
Short Term Debt Incl. Current Port. of LT Debt	9.00	8.00	11.00	-	11.00	-
Accounts Payable	251.00	163.00	303.00	-	205.00	-
Income Tax Payable	34.00	38.00	-	-	0.00	-
Other Current Liabilities	488.00	493.00	382.00	-	494.00	-
Total Current Liabilities	782.00	702.00	696.00	-	710.00	-
Long Term Debt	50.00	45.00	50.00	-	56.00	-
Provision for Risks Charges	52.00	59.00	105.00	-	80.00	-
Other Liabilities	214.00	213.00	29.00	-	25.00	-
Total Liabilities	1,098.00	1,019.00	880.00	-	871.00	-
Non-Equity Reserves	0.00	0.00	0.00	-	0.00	-
Preferred Stock - Carrying Value	0.00	0.00	0.00	-	0.00	-
Common Equity	3,620.00	3,611.00	3,462.00	-	3,330.00	-
Total Shareholders Equity	3,620.00	3,611.00	3,462.00	-	3,330.00	-
Accumulated Minority Interest	0.00	0.00	0.00	-	0.00	-
Total Equity	3,620.00	3,611.00	3,462.00	-	3,330.00	-
Total Liabilities & Stockholders Equity	4,718.00	4,630.00	4,342.00	-	4,201.00	-
Book Value Per Share	12.87	12.86	12.33	-	11.86	-
Tangible Book Value Per Share	4.50	4.44	3.89	-	3.36	-
Full-Time Employees	-	8,000	-	-	-	-
Price to Book Ratio	1.35	1.00	0.97	-	-	-
Return on Invested Capital	0.00	-5.01	-3.39	-	-5.08	-
Quick Ratio	1.36	1.43	1.01	-	0.88	-
Current Ratio	1.81	1.92	1.59	-	1.32	-

Cash flow, quarterly

Currency USD, millions
Metric	2026Q1	2025Q4	2025Q3	2025Q1	2024Q4	2024Q3
Net Income	0.00	-185.00	-	-16.00	-168.00	-
Depreciation	41.00	39.00	-	39.00	38.00	-
Other Funds (Non Cash)	18.00	19.00	-	24.00	21.00	-
Funds from Operations	61.00	-182.00	-	47.00	-111.00	-
Extraordinary Item	0.00	0.00	-	0.00	0.00	-
Changes in Working Capital	-110.00	12.00	-	-188.00	194.00	-
Cash from Operating Activities	-49.00	-170.00	-	-141.00	83.00	-
Capital Expenditures	-41.00	-56.00	-	-53.00	-57.00	-
Net Assets From Acquisitions	0.00	0.00	-	0.00	0.00	-
Sale of Fixed Assets and Businesses	0.00	0.00	-	0.00	0.00	-
Purchase or Sale of Investments	0.00	0.00	-	0.00	0.00	-
Purchase of Investments	0.00	0.00	-	0.00	0.00	-
Sale Or Maturity of Investments	0.00	0.00	-	0.00	0.00	-
Other Uses	0.00	0.00	-	-10.00	0.00	-
Other Sources	0.00	0.00	-	0.00	0.00	-
Cash from Investing Activities	-41.00	-56.00	-	-63.00	-57.00	-
Cash Dividends Paid	0.00	-229.00	-	0.00	-2.00	-
Preferred Dividends (Cash Flow)	0.00	0.00	-	0.00	0.00	-
Change in Capital Stock	0.00	538.00	-	0.00	0.00	-
Repurchase of Common Pref Stock	0.00	0.00	-	0.00	0.00	-
Sale of Common Pref Stock	0.00	538.00	-	0.00	0.00	-
Proceedsfrom Stock Options	0.00	538.00	-	0.00	0.00	-
Issuance or Reduction of Debt, Net	0.00	0.00	-	0.00	0.00	-
Change in Long Term Debt	0.00	0.00	-	0.00	0.00	-
Issuance of Long Term Debt	0.00	0.00	-	0.00	0.00	-
Reduction of Long Term Debt	0.00	0.00	-	0.00	0.00	-
Net Financing Active Other Cash Flow	0.00	203.00	-	202.00	-23.00	-
Other Financing Activities Uses	0.00	0.00	-	0.00	2.00	-
Cash from Financing Activities	0.00	512.00	-	202.00	-25.00	-
Exchange Rate Effect	-1.00	-	-	0.00	-	-
Net Change in Cash	-91.00	287.00	-	-2.00	1.00	-
Free Cash Flow	-90.00	-226.00	-	-194.00	26.00	-

Revenue breakdown

Consolidation, Policy	2025: 1.00M
Consumables	2025: 956.00M
Continuous Glucose Monitoring Systems (CGM)	2025: 1.55B
Product and Service, Other	2025: 46.00M
Pumps	2025: 546.00M
Non-US	2025: 2.19B
United States	2025: 917.00M

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	3.51%	9.8M	279.8M	7.11M
2026-10-15	7.40%	20.7M	279.8M	5.59M
2026-09-30	66.98%	18.2M	27.2M	1.77M
2026-09-15	50.04%	13.6M	27.2M	1.49M
2026-08-31	30.18%	8.1M	26.7M	1.22M
2026-08-14	22.64%	5.9M	26.1M	1.09M
2026-07-31	23.15%	6.0M	26.0M	1.02M
2026-07-15	24.44%	6.3M	26.0M	925.15K
2026-06-30	25.31%	6.6M	26.0M	957.96K
2026-06-15	16.79%	4.6M	27.2M	830.68K
2026-05-29	14.46%	4.0M	27.9M	995.54K
2026-05-15	15.30%	4.3M	27.9M	1.06M
2026-04-30	13.09%	3.7M	27.9M	1.18M
2026-04-15	-	2.9M	-	1.35M
2026-03-31	-	2.8M	-	1.54M
2026-03-13	-	1.3M	-	3.02M

Option chain

expiry 2026-11-20

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
call	2.50	14.00	16.30	12.92	10.905	0.00	0.00	0.994	-0.018	0.000
call	5.00	11.50	13.90	10.00	7.355	0.00	0.00	0.990	-0.018	0.001
call	7.50	9.20	12.00	7.92	6.689	0.00	0.00	0.985	-0.018	0.001
call	10.00	6.70	8.80	7.75	3.636	551	0.00	0.979	-0.017	0.001
call	12.50	4.20	7.70	6.70	2.551	6.00	0.00	0.970	-0.016	0.002
call	15.00	2.30	3.80	2.50	1.636	16.00	0.00	0.922	-0.023	0.004
call	17.50	1.00	1.55	1.15	1.020	11,974	1.00	0.652	-0.049	0.011
call	19.00	0.25	0.60	0.43	0.798	5,009	18.00	0.423	-0.060	0.011
call	20.00	0.15	0.25	0.18	0.711	10,816	8,362	0.224	-0.034	0.009
call	21.00	0.00	0.75	0.00	0.923	0.00	0.00	0.185	-0.040	0.008
call	22.50	0.00	0.20	0.06	1.116	41.00	0.00	0.134	-0.039	0.006
call	25.00	0.00	0.20	0.14	1.480	48.00	0.00	0.108	-0.044	0.005
call	30.00	0.00	0.95	1.17	2.059	4.00	0.00	0.084	-0.051	0.004
call	35.00	0.00	0.95	0.10	2.511	3.00	0.00	0.072	-0.055	0.004
put	2.50	0.00	0.05	0.00	5.927	0.00	0.00	-0.007	-0.016	0.001
put	5.00	0.00	0.05	0.00	3.834	0.00	0.00	-0.011	-0.016	0.001
put	7.50	0.00	0.95	0.15	2.906	1.00	0.00	-0.015	-0.017	0.001
put	10.00	0.00	0.25	0.10	2.044	11.00	0.00	-0.021	-0.016	0.001
put	12.50	0.00	0.05	0.10	1.605	3.00	0.00	-0.047	-0.025	0.003
put	15.00	0.00	0.10	0.10	0.932	989	0.00	-0.078	-0.022	0.004
put	17.50	0.40	0.50	0.40	0.735	12,463	1,995	-0.348	-0.048	0.011
put	19.00	0.70	2.90	1.93	1.332	0.00	0.00	-0.577	-0.058	0.011
put	20.00	1.60	1.95	2.80	0.656	181	0.00	-0.777	-0.032	0.009
put	21.00	2.15	4.10	0.00	2.048	0.00	0.00	-0.815	-0.037	0.008
put	22.50	3.70	5.70	3.80	2.484	10.00	0.00	-0.866	-0.036	0.006
put	25.00	5.50	8.30	7.35	3.074	0.00	0.00	-0.892	-0.041	0.005
put	30.00	10.30	13.50	11.39	4.042	5.00	0.00	-0.916	-0.047	0.004
put	35.00	16.20	18.50	0.00	4.635	0.00	0.00	-0.928	-0.051	0.004

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-06	SCHEDULE 13G			SEC
2026-10-30	4	Statement of changes in beneficial ownership of securities	2026-10-28	SEC
2026-10-22	SCHEDULE 13G			SEC
2026-10-19	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-19	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-19	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-16	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-16	3	Initial statement of beneficial ownership of securities	2026-10-15	SEC
2026-10-16	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-16	SCHEDULE 13G/A			SEC
2026-10-16	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-16	4	Statement of changes in beneficial ownership of securities	2026-10-15	SEC
2026-10-16	8-K	Current report	2026-10-15	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-09	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-09	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-09	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-09	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-09	SEC
2026-10-13	8-K	Current report	2026-10-09	SEC
2026-10-05	EFFECT	Effectiveness filing by commission order		SEC
2026-10-05	4	Statement of changes in beneficial ownership of securities	2026-10-01	SEC
2026-10-05	424B3			SEC
2026-10-01	3	Initial statement of beneficial ownership of securities	2026-09-25	SEC
2026-09-21	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC
2026-09-21	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC
2026-09-14	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC
2026-09-14	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC
2026-09-14	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC
2026-09-14	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC
2026-09-14	425	Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.		SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	0	0
2026-10	0	0	0	0
2026-09	0	0	0	0
2026-08	0	0	0	0
2026-07	0	0	0	0
2026-06	0	0	0	0
2026-05	0	0	0	0
2026-04	0	0	0	0
2026-03	0	0	0	0
2026-02	0	0	0	0
2026-01	0	0	0	0
2025-12	0	0	0	0
2025-11	0	0	0	0

Institutional holders

Manager	% owned
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	2.97%
FMR LLC	1.21%
MILLENNIUM MANAGEMENT LLC	1.09%
CITADEL ADVISORS LLC	1.02%
Longaeva Partners L.P.	1.00%
UBS Group AG	0.97%
Sessa Capital IM, L.P.	0.71%
BlackRock, Inc.	0.71%
NORGES BANK	0.70%
Rock Springs Capital Management LP	0.54%

Funds

Fund	% owned
MFS Mid Cap Value Fund	1.52%
Select Medical Technology and Devices Portfolio	0.66%
MFS New Discovery Value Fund	0.32%
MFS New Discovery Fund	0.31%
iShares Russell 2000 ETF	0.27%
MFS Mid Cap Growth Fund	0.26%
JNL/MFS Mid Cap Value Fund	0.17%
Bridge Builder Small/Mid Cap Value Fund	0.17%
Nuveen Quant Small Cap Equity Fund	0.14%
First Trust US Equity Opportunities ETF	0.13%

OakChart. MMED. Cached 15 minutes.

Some panels did not load: insider.